WCN26-5458 Hemoperfusion as Adjunctive Therapy in Sepsis in an Immunocompromised Host with Systemic Lupus Erythematosus: A Case Report

Read full text Summarise with VIRAT
Authors: MARIKA ILYSHA LAPIDARIO, Stephen Roberts
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease marked by immune dysregulation that predisposes affected individuals to life-threatening infections. Sepsis is a major cause of morbidity and mortality in SLE due to impaired pathogen clearance, immune exhaustion, and cytokine overproduction. In the setting of overwhelming inflammation, conventional management with antibiotics, corticosteroids, and supportive care may be insufficient to prevent deterioration. Hemoperfusion (HP) is an extracorporeal blood purification therapy that adsorbs circulating cytokines and endotoxins, thereby mitigating hyperinflammatory states associated with septic shock.

Fields of Study & Subjects

Sepsis Diagnosis and Treatment Systemic Lupus Erythematosus Research Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105271–105271
Publication date
25 March 2026
Language
EN